Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

Keyphrases

• Pembrolizumab 100%
• Nivolumab 100%
• Anti-PD-1 Therapy 100%
• Cutaneous Adverse Reaction 100%
• Life-threatening 50%
• Anticancer Therapy 50%
• Cutaneous Reaction 50%
• Skin Manifestations 50%
• Anti-programmed death-1 Monoclonal Antibody 50%
• Adverse Cutaneous Reactions 50%

Neuroscience

• Nivolumab 100%
• Lambrolizumab 100%
• Systematic Review 100%
• Cell Death 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Skin Manifestation 100%
• Nivolumab 66%
• Pembrolizumab 66%
• Malignant Neoplasm 33%
• Programmed Cell Death 33%